A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT)

Haematologica

Volumn 83, Issue 2, 1998, Pages 132-137

  Zikos, Pannos ^a   Van Lint, Maria Teresa ^a   Lamparelli, Teresa ^a   Gualandi, Francesca ^a   Occhini, Domenico ^a   Mordini, Nicola ^a   Berisso, Gianni ^a   Bregante, Stefania ^a   Bacigalupo, Andrea ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Bone marrow transplantation; Cytomegalovirus hyperimmune IgG; Hemopoietic stem cells transplants; Intravenous IgG

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; HIGH DOSE INTRAVENOUS IMMUNOGLOBULIN G; HYPERIMMUNE CYTOMEGALOVIRUS IMMUNOGLOBULIN G; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; THIOTEPA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CAUSE OF DEATH; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INFECTION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0031893542     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Meyers JD. Infection in bone marrow transplant recipients. Am J Med 1986; 81:27.
2. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153:478-8.
3. Miller W, Flynn P, McCullough, J et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-versus-host disease. Blood 1986; 67:1162-7.
4. Sullivan K. Immunoglobulin therapy in bone marrow transplantation. Am J Med 1987; 83(suppl 4A):34-45.
5. Condie RM, O'Reilly RJ. Prevention of cytomegalovirus infection by prophylaxis with intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplants recipients. Am J Med 1984; 76(suppl 3A): 134-41.
6. Zaia JA, Levin Mj, Leszczynski J, Wright GG, Grady GF. Cytomegalovirus immune globulin: production from selected normal donor blood. Transplantation 1979; 27:66-7.
7. Winston DJ, Pollard RB, Ho WG, et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 1982; 97:11-8.
8. Rindgen O, Pihlstedt P, Volin L, et al. Failure to prevent cytomegalovirus infection by cytomegalovirus immune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transpl 1987; 2:299-305.
9. Bowden RA, Sayers M, Flournoy N, et al: Cytomegalovirus immune globulin and seronegative blood products to prevent to prevent primary cytomegalovirus infection after marrow transplant. N Engl J Med 1986; 314:1006-10.
10. Schmeister T, Arnold R, Wiesneth M, Bunjes D, Heimpel H, Heit W. CMV-IgG-hyperimmunoglobulin for the prevention of CMV-infection in BMT-recipients [abstract]. Bone Marrow Transpl 1986; 1 (suppl 1):64.
11. Sullivan KM, Kopesky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323:705-12.
12. Majolino I. Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation group (GITMO). Haematologica 1997; 82:47-52.
13. Majolino I. Peripheral blood stem cells for allogeneic transplantation. Recommendations from the GITMO 1996. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica 1996; 81:529-32.
14. Bacigalupo A, van Lint MT, Tedone E, et al. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transpl 1994; 13:753-8.
15. Chehimi J, Peppard J, Emanuel D. Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: an in vitro comparison of currently available and previously effective immune globulins. Bone Marrow Transpl 1987; 2:395-402.
16. Bacigalupo A, Tedone E, Van Lint MT, et al. CMV prophylaxis with Foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transpl 1994; 13: 783-8.
17. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-60.
18. Tutschka PJ, Copelan EA. Experience with Sandoglobulin in bone marrow transplantation. Int J Cell Cloning 1986; 4:181-8.
19. Blacklock HA, Griffiths P, Stirk P, Prentice HG. Specific hyperimmune globulin for cytomegalovirus pneumonitis [letter]. Lancet 1985; 2:152-3.
20. Reed E, Bowden R, Dandliker P, Lilleby K, Meyers J. Treatment of cytomegalovirus pneumonia with gancyclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplantation. Ann Intern Med 1988; 109:783-8.
21. Bacigalupo A, Bregante S, Tedone E, et al. Combined Foscarnet-ganciclovir treatment for cytomegalovirus infections aftrer allogeneic hemopoietic stem cell transplantation. Transplantation 1996; 62:376-80.
22. Ruutu T, Ljungman P, Brinch L, et al. No prevention of cytomegalovirus infection by anticytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. Bone Marrow Transpl 1997; 19:233-6.
23. Boeckh M, Gooley T, Myerson D, Cunningham T, Schoch G, Bowden R. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88:4063-71.
24. Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19:287-98.
25. Scaradavou A, Woo B, Woloski BMR, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89:2689-700.
26. The American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. Ann Intern Med 1997; 126:319-26.
27. Ferrara J, Deeg H. Graft versus host disease. N Engl J Med 1990; 324:667-74.
28. Winston DJ, Antin JH, Wolff S, et al. Comparative efficacy of different doses of intravenous immunoglobulin (IVIG) for prevention of graft-versus-host disease (GVHD) after bone marrow transplantation (BMT) [abstract]. Blood 1996; 88:(suppl 1):302a.
29. Wolff S, Winston D, Antin J, et al. Multi center randomized double-blind dose response trial of IVIG for the prevention of infection after allogeneic bone marrow transplantation (ALLO-BMT) [abstract]. Blood 1996; 88:10 (suppl 1):303a.